Max Petersson
Directeur des opérations chez Accuro Immunology AB
Profil
Max Petersson is Chief Operating Officer of Accuro Immunology AB.
He was a Researcher and an Assistant Professor of Karolinska Institute.
He received a PhD from Karolinska Institute.
Postes actifs de Max Petersson
| Sociétés | Poste | Début |
|---|---|---|
Accuro Immunology AB
 Accuro Immunology AB Pharmaceuticals: MajorHealth Technology Accuro Immunology AB develops and manufactures active immunotherapy products. The firm's products help to treat the patients suffering from problems with immune escape/evasion. The company was founded by Peter Gunnar Maurits Wolpert and Elisabeth Wolpert in 1999 and is headquartered in Stockholm, Sweden. | Directeur des opérations | - |
Anciens postes connus de Max Petersson
| Sociétés | Poste | Fin |
|---|---|---|
AngioGenetics AB
 AngioGenetics AB Pharmaceuticals: GenericHealth Technology AngioGenetics AB develops, markets, and distributes generic drugs. It develops angiogenesis modulating drugs for the treatment of cancer, ischemic heart disease, and eye diseases. The company was founded in June 2001 and is headquartered in Göteborg, Sweden. | Corporate Officer/Principal | - |
Formation de Max Petersson
| Karolinska Institutet | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Accuro Immunology AB
Accuro Immunology AB Pharmaceuticals: MajorHealth Technology Accuro Immunology AB develops and manufactures active immunotherapy products. The firm's products help to treat the patients suffering from problems with immune escape/evasion. The company was founded by Peter Gunnar Maurits Wolpert and Elisabeth Wolpert in 1999 and is headquartered in Stockholm, Sweden. | Health Technology |
AngioGenetics AB
AngioGenetics AB Pharmaceuticals: GenericHealth Technology AngioGenetics AB develops, markets, and distributes generic drugs. It develops angiogenesis modulating drugs for the treatment of cancer, ischemic heart disease, and eye diseases. The company was founded in June 2001 and is headquartered in Göteborg, Sweden. | Health Technology |
